[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555731":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"East and North Hertfordshire NHS Trust","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"HDF patients",null,"ESRF patients who are receiving renal replacement therapy in the form of HDF",[13],{"name":14,"affiliation":5,"role":15},"Usama A Butt, MBBS, MRCP","PRINCIPAL_INVESTIGATOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Usama A Butt, MBBS,MRCP","CONTACT","+441438284340","usama.butt1@nhs.net",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Stevenage","Hertfordshire","SG1 4AB","United Kingdom","UK",{"type":31,"coordinates":32},"Point",[33,34],-0.20256,51.90224,{"lat":34,"lon":33},[37,39],{"name":18,"role":19,"phone":38,"phoneExt":10,"email":21},"+441438 284340",{"name":18,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100555731","association-of-middle-molecules-clearance-with-hdf-volume-100555731",false,"NCT06515899","Association of Middle Molecules Clearance With HDF Volume","Association of Middle Molecules Clearance and Clinical Parameters With Haemodiafiltration Convection Volume","Inclusion Criteria:\n\n* Age 18 years or above.\n* Ability to give informed consent.\n* End stage renal failure treated by dialysis for at least 3 months.\n* Established on hemodiafiltration for \\>4 weeks.\n* Prognosis more than 6 months as assessed by PI\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Inability to give informed consent.\n* Prognosis less than 6 months as assessed by PI","ALL","18 Years",{"count":52,"type":53},400,"ESTIMATED","OBSERVATIONAL","HDF is a dialysis technique which involves diffusion and convection. HDF with high convection volume has consistently shown to improve survival in dialysis patients in number of robust RCTs. The precise reason of this survival benefit remains unclear.\n\nThe investigators hypothesize that this survival benefit with high volume HDF is related to enhanced middle molecule clearance and hemodynamic stability. However, this relationship has not been studied so far.\n\nThis observational study is aimed to understand the relationship between HDF convection volume with middle molecules (Beta 2-Microglobulin) clearance during HDF.\n\nExploring the relationship of HDF volume with middle molecules clearance has significant clinical ramifications. Only a minority of patients are able to achieve target convection volume. Understanding these relationships can rationalize the HDF prescription from convection volume-based prescription to β2-Microglobulin clearance-based prescription which may be applicable to wider range of patients.\n\nThe relationship between pre-dialysis β2-Microglobulin levels and RKF offers the prospect of dispensing with pre- and post-dialysis urea and creatinine measurements and interdialytic urine collections, currently necessary for estimating RKF, thus simplifying its estimation.\n\nβ2-Microglobulin reduction ratio and its component pre and post-dialysis β2-Microglobulin levels could therefore provide a composite estimate of small and middle molecule clearance and RKF.",[57],"End Stage Renal Disease",[59,60,61,62,63],"Middle Molecules clearance in HDF","HDF","Middle molecules","beta 2 microglobulin","HDF convection volume","2024-07-17",{"date":66,"type":67},"2024-07-23","ACTUAL",{"date":69,"type":67},"2024-01-19",{"date":71,"type":53},"2025-07",{"name":5,"class":6},1]